Alzheimer's Disease: A New Paradigm, New Treatments, New Challenges, New Approaches
Open Access
- 7 August 2025
- journal article
- Published by Journal of Health Systems and Policies, Istanbul Medipol University in Journal of Health Systems and Policies
- Vol. 7 (1) , 59-76
Abstract
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide. Recent advances in biomarker-based diagnostics and disease-modifying therapies have shifted the landscape of AD from symptom management to early intervention. This review examines current therapeutic innovations, with a particular focus on monoclonal antibodies such as lecanemab, aducanumab, and donanemab. While these agents show potential in slowing disease progression by targeting amyloid-beta accumulation, concerns remain regarding their clinical efficacy, safety profiles, and cost-effectiveness—especially in aging populations with high healthcare burdens. Additionally, developments in biological diagnosis through fluid and imaging biomarkers have introduced new ethical and policy-related challenges. The paper also highlights the role of non-pharmacological interventions, such as multidomain lifestyle programs, in enhancing cognitive reserve and delaying disease onset. Finally, the article calls for a comprehensive public health approach that includes precision medicine, national screening strategies, and policy reforms to address the growing societal impact of Alzheimer’s disease.Keywords
This publication has 28 references indexed in Scilit:
- Lecanemab’s Path Forward: Navigating the Future of Alzheimer’s Treatment in Europe Amidst the EMA's RejectionNeurology and Therapy, 2024
- Morphological and Molecular Profiling of Amyloid-β Species in Alzheimer’s PathogenesisMolecular Neurobiology, 2024
- Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association WorkgroupAlzheimer's & Dementia, 2024
- Alzheimer's disease drug development pipeline: 2024Alzheimer's & Dementia: Translational Research & Clinical Interventions, 2024
- Effect of Personalized Risk-Reduction Strategies on Cognition and Dementia Risk Profile Among Older AdultsJAMA Internal Medicine, 2024
- Relationship between baseline plasma p‐tau181 and longitudinal changes in cognition and structural brain measures in a cohort of cognitively unimpaired older adultsAlzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring, 2023
- The affordability of lecanemab, an amyloid-targeting therapy for Alzheimer's disease: an EADC-EC viewpointThe Lancet Regional Health - Europe, 2023
- The Alzheimer’s Disease Clinical SpectrumMedical Clinics of North America, 2019
- Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical diseaseAlzheimer's & Dementia, 2018
- NIA‐AA Research Framework: Toward a biological definition of Alzheimer's diseaseAlzheimer's & Dementia, 2018